(a) Cp 090104 and CP-derived BLPs enhance the adaptive immune responses against pneumococcal infection, (b) Cp 090104 and CP-derived BLPs enhance the adaptive immune responses induced by pneumococcal vaccines and boost resistance to primary pneumococcal infection, and (c) Cp 090104 and CP-derived BLPs improve the adaptive immune responses induced by pneumococcal vaccines and enhance resistance to secondary pneumococcal infection. This evidence concerns the gene CP and pneumococcal infection.